Targeting PGLYRP1 promotes antitumor immunity while inhibiting autoimmune neuroinflammation.
Schnell A, Huang L, Regan BML, Singh V, Vonficht D, Bollhagen A, Wang M, Hou Y, Bod L, Sobel RA, et al. Nat Immunol. 2023 Nov; 24(11):1908-1920. Epub 2023 Oct 12.